Navigation Links
Acrongenomics Acquires Equity Stake in Molecular Vision
Date:2/4/2008

GENEVA, February 4 /PRNewswire-FirstCall/ -- Acrongenomics, Inc. (OTC: AGNM) is pleased to announce that they have acquired a 10.9% interest in Molecular Vision Limited, on a fully diluted basis. The cash consideration will be used by Molecular Vision for working capital and to further develop its technology.

Molecular Vision is developing low cost easy-to-use credit-card sized devices for medical testing that will greatly extend the in-house tools available to the general practitioner. The devices are being developed to allow near patient quantitative diagnosis, currently focusing on key areas of high disease burden, namely kidney function and cardiovascular disease. The technology also has additional applications outside the diagnostics market (e.g. forensic science, homeland security and environmental monitoring).

About Acrongenomics Inc.

Acrongenomics Inc. is a publicly traded company that focuses on investing in and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications. The company has its headquarters in Geneva, Switzerland.

About Molecular Vision Limited

Molecular Vision Limited is a spin-out company of Imperial college, London UK. The company was founded by three Imperial College London researchers - Prof. Donal Bradley, Prof. Andrew De Mello and Dr. John De Mello - in 2002 in order to meet a clearly defined demand in the medical diagnostics, biosensors and analytical instrumentations markets and the need for miniaturized chemical and biological detectors offering high sensitivity and functionality at low cost. The company has directly addressed this market demand by inventing a novel method for optical detection based on recent advances in organic electronics and light emitting diodes combined with microfluidics technology. The company has mainly focused on applying its technology to the medical diagnostics markets.

Important Information About Forward-Looking Statements

All statements in this news release that are other than statements of historical facts are forward-looking statements which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates", "believes", "could", "expects", "intends", "may", "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions. For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB, and subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances, new information, future events, or for any other reason occurring after the date of this news release.

For more information contact:

Acrongenomics Inc.

Platon M Tzouvalis

President

Tel: +41-22-716-5300

Fax: +41-22-716-5319

http://www.acrongen.com


'/>"/>
SOURCE Acrongenomics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
2. Neogen Acquires Kane Enterprises
3. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
4. Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
5. United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider
6. NSF International Acquires David Begg Associates
7. United BioSource Acquires Caro Research, Leader in Simulation Modeling
8. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
9. Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services
10. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
11. Thermo Fisher Scientific Acquires Leader in Micro-Volume Spectrophotometers, NanoDrop Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 25, 2017 , ... LABS, Inc. (LABS) announced ... added to its extensive test menu: Nucleic Acid Testing (NAT) for ZIKV; and Enzyme ... only able to offer NAT screening for blood donors under an Investigational New Drug ...
(Date:4/25/2017)... ... , ... As part of the Stago EdVantage Virtual University Virtual ... in order to illuminate this clinical problem for people unfamiliar with the topic. , ... a high degree of morbidity and mortality. DIC is a confusing disorder from both ...
(Date:4/25/2017)... California (PRWEB) , ... April 25, 2017 , ... ... Analytical Services and Metrology Partners.     , Covalent’s Analytical Services unit provides ... samples can be measured within 24 hours of receipt. There are no price ...
(Date:4/21/2017)... ... 21, 2017 , ... Having worked on the design of the innovative ... it to top lab design architects from around the country at the Lab Design ... Design and Engineering Greg Casey will be at the show, where they will highlight ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
Breaking Biology News(10 mins):